AC
FLNA

Armistice Capital’s Filana Therapeutics FLNA Stock Holding History

Armistice Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,164,000
Closed -$2.19M – 93
2018
Q3 		$2.19M Buy
+2,164,000
New +$3.29M 0.13% 69

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital's FLNA Position: Q4 2018 in Review

Armistice Capital sold out of Filana Therapeutics (FLNA) in Q4 2018, closing a stake of 2,164,000 shares — an estimated $2.19M sold.

Armistice Capital first reported a position in FLNA in Q3 2018 and held it in 1 quarter. The position peaked at $2.19M in Q3 2018. 25 funds tracked by Wall St. Rank hold FLNA as of Q4 2018.

  • Armistice Capital reported no remaining Filana Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Armistice Capital sold 2,164,000 Filana Therapeutics shares in Q4 2018, an estimated $2.19M.
  • Armistice Capital first reported a position in Filana Therapeutics in Q3 2018 and held it in 1 quarter.
  • Armistice Capital's Filana Therapeutics position peaked at $2.19M in Q3 2018.
  • 25 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2018.

Based on Armistice Capital's 13F filing for Q4 2018, filed 14 Feb 2019.